 | • レポートコード：GIR-22F19673 • 出版社/出版日：GlobalInfoResearch / 2022年11月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Trastuzumab Emtansine for Injection Market 2022」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社の最新の調査によると、世界の注射用トラスツズマブエムタンシンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 注射用トラスツズマブエムタンシン市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次をカバーします。 ・60mg、100mg、150mg、160mg、その他 アプリケーション別セグメントは次のように区分されます。 ・病院、診療所、その他 世界の注射用トラスツズマブエムタンシン市場の主要な市場プレーヤーは以下のとおりです。 ・Genentech、Daiichi Sankyo、Amgen、Pfizer、Samsung Bioepis、Mylan(Viatris)、Celltrion、Roche、Accord Healthcare、Nippon Kayaku、Chugai Pharmaceutical、Henlius、Orifarm 地域別セグメントは次の地域・国をカバーします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、注射用トラスツズマブエムタンシン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な注射用トラスツズマブエムタンシンメーカーの企業概要、2019年～2022年までの注射用トラスツズマブエムタンシンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な注射用トラスツズマブエムタンシンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別注射用トラスツズマブエムタンシンの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの注射用トラスツズマブエムタンシンのタイプ別とアプリケーション別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での注射用トラスツズマブエムタンシン市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および注射用トラスツズマブエムタンシンの産業チェーンを掲載しています。 ・第13、14、15章では、注射用トラスツズマブエムタンシンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 注射用トラスツズマブエムタンシンの概要 - タイプ別分析（2017年vs2021年vs2028年）：60mg、100mg、150mg、160mg、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、診療所、その他 - 世界の注射用トラスツズマブエムタンシン市場規模・予測 - 世界の注射用トラスツズマブエムタンシン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Genentech、Daiichi Sankyo、Amgen、Pfizer、Samsung Bioepis、Mylan(Viatris)、Celltrion、Roche、Accord Healthcare、Nippon Kayaku、Chugai Pharmaceutical、Henlius、Orifarm ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：60mg、100mg、150mg、160mg、その他 ・アプリケーション別分析2017年-2028年：病院、診療所、その他 ・注射用トラスツズマブエムタンシンの北米市場分析 - 注射用トラスツズマブエムタンシンの北米市場：タイプ別市場規模2017年-2028年 - 注射用トラスツズマブエムタンシンの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・注射用トラスツズマブエムタンシンのヨーロッパ市場分析 - ：注射用トラスツズマブエムタンシンのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：注射用トラスツズマブエムタンシンのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・注射用トラスツズマブエムタンシンのアジア太平洋市場分析 - 注射用トラスツズマブエムタンシンのアジア太平洋市場：タイプ別市場規模2017年-2028年 - 注射用トラスツズマブエムタンシンのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・注射用トラスツズマブエムタンシンの南米市場分析 - 注射用トラスツズマブエムタンシンの南米市場：タイプ別市場規模2017年-2028年 - 注射用トラスツズマブエムタンシンの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・注射用トラスツズマブエムタンシンの中東・アフリカ市場分析 - 注射用トラスツズマブエムタンシンの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 注射用トラスツズマブエムタンシンの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Trastuzumab Emtansine for Injection market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Trastuzumab Emtansine for Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospitals accounting for % of the Trastuzumab Emtansine for Injection global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 60mg segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Trastuzumab Emtansine for Injection include Genentech, Daiichi Sankyo, Amgen, Pfizer, and Samsung Bioepis, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Trastuzumab Emtansine for Injection market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
60mg
100mg
150mg
160mg
Others
Market segment by Application can be divided into
Hospitals
Clinics
Others
The key market players for global Trastuzumab Emtansine for Injection market are listed below:
Genentech
Daiichi Sankyo
Amgen
Pfizer
Samsung Bioepis
Mylan(Viatris)
Celltrion
Roche
Accord Healthcare
Nippon Kayaku
Chugai Pharmaceutical
Henlius
Orifarm
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Trastuzumab Emtansine for Injection product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Trastuzumab Emtansine for Injection, with price, sales, revenue and global market share of Trastuzumab Emtansine for Injection from 2019 to 2022.
Chapter 3, the Trastuzumab Emtansine for Injection competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Trastuzumab Emtansine for Injection breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Trastuzumab Emtansine for Injection market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Trastuzumab Emtansine for Injection.
Chapter 13, 14, and 15, to describe Trastuzumab Emtansine for Injection sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Trastuzumab Emtansine for Injection Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Trastuzumab Emtansine for Injection Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 60mg
1.2.3 100mg
1.2.4 150mg
1.2.5 160mg
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Trastuzumab Emtansine for Injection Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Trastuzumab Emtansine for Injection Market Size & Forecast
1.4.1 Global Trastuzumab Emtansine for Injection Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Trastuzumab Emtansine for Injection Sales in Volume (2017-2028)
1.4.3 Global Trastuzumab Emtansine for Injection Price (2017-2028)
1.5 Global Trastuzumab Emtansine for Injection Production Capacity Analysis
1.5.1 Global Trastuzumab Emtansine for Injection Total Production Capacity (2017-2028)
1.5.2 Global Trastuzumab Emtansine for Injection Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Trastuzumab Emtansine for Injection Market Drivers
1.6.2 Trastuzumab Emtansine for Injection Market Restraints
1.6.3 Trastuzumab Emtansine for Injection Trends Analysis
2 Manufacturers Profiles
2.1 Genentech
2.1.1 Genentech Details
2.1.2 Genentech Major Business
2.1.3 Genentech Trastuzumab Emtansine for Injection Product and Services
2.1.4 Genentech Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Daiichi Sankyo
2.2.1 Daiichi Sankyo Details
2.2.2 Daiichi Sankyo Major Business
2.2.3 Daiichi Sankyo Trastuzumab Emtansine for Injection Product and Services
2.2.4 Daiichi Sankyo Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Trastuzumab Emtansine for Injection Product and Services
2.3.4 Amgen Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Trastuzumab Emtansine for Injection Product and Services
2.4.4 Pfizer Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Samsung Bioepis
2.5.1 Samsung Bioepis Details
2.5.2 Samsung Bioepis Major Business
2.5.3 Samsung Bioepis Trastuzumab Emtansine for Injection Product and Services
2.5.4 Samsung Bioepis Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Mylan(Viatris)
2.6.1 Mylan(Viatris) Details
2.6.2 Mylan(Viatris) Major Business
2.6.3 Mylan(Viatris) Trastuzumab Emtansine for Injection Product and Services
2.6.4 Mylan(Viatris) Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Celltrion
2.7.1 Celltrion Details
2.7.2 Celltrion Major Business
2.7.3 Celltrion Trastuzumab Emtansine for Injection Product and Services
2.7.4 Celltrion Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business
2.8.3 Roche Trastuzumab Emtansine for Injection Product and Services
2.8.4 Roche Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Trastuzumab Emtansine for Injection Product and Services
2.9.4 Accord Healthcare Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Nippon Kayaku
2.10.1 Nippon Kayaku Details
2.10.2 Nippon Kayaku Major Business
2.10.3 Nippon Kayaku Trastuzumab Emtansine for Injection Product and Services
2.10.4 Nippon Kayaku Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Chugai Pharmaceutical
2.11.1 Chugai Pharmaceutical Details
2.11.2 Chugai Pharmaceutical Major Business
2.11.3 Chugai Pharmaceutical Trastuzumab Emtansine for Injection Product and Services
2.11.4 Chugai Pharmaceutical Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Henlius
2.12.1 Henlius Details
2.12.2 Henlius Major Business
2.12.3 Henlius Trastuzumab Emtansine for Injection Product and Services
2.12.4 Henlius Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Orifarm
2.13.1 Orifarm Details
2.13.2 Orifarm Major Business
2.13.3 Orifarm Trastuzumab Emtansine for Injection Product and Services
2.13.4 Orifarm Trastuzumab Emtansine for Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Trastuzumab Emtansine for Injection Breakdown Data by Manufacturer
3.1 Global Trastuzumab Emtansine for Injection Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Trastuzumab Emtansine for Injection Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Trastuzumab Emtansine for Injection
3.4 Market Concentration Rate
3.4.1 Top 3 Trastuzumab Emtansine for Injection Manufacturer Market Share in 2021
3.4.2 Top 6 Trastuzumab Emtansine for Injection Manufacturer Market Share in 2021
3.5 Global Trastuzumab Emtansine for Injection Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Trastuzumab Emtansine for Injection Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Trastuzumab Emtansine for Injection Market Size by Region
4.1.1 Global Trastuzumab Emtansine for Injection Sales in Volume by Region (2017-2028)
4.1.2 Global Trastuzumab Emtansine for Injection Revenue by Region (2017-2028)
4.2 North America Trastuzumab Emtansine for Injection Revenue (2017-2028)
4.3 Europe Trastuzumab Emtansine for Injection Revenue (2017-2028)
4.4 Asia-Pacific Trastuzumab Emtansine for Injection Revenue (2017-2028)
4.5 South America Trastuzumab Emtansine for Injection Revenue (2017-2028)
4.6 Middle East and Africa Trastuzumab Emtansine for Injection Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Trastuzumab Emtansine for Injection Sales in Volume by Type (2017-2028)
5.2 Global Trastuzumab Emtansine for Injection Revenue by Type (2017-2028)
5.3 Global Trastuzumab Emtansine for Injection Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Trastuzumab Emtansine for Injection Sales in Volume by Application (2017-2028)
6.2 Global Trastuzumab Emtansine for Injection Revenue by Application (2017-2028)
6.3 Global Trastuzumab Emtansine for Injection Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Trastuzumab Emtansine for Injection Sales by Type (2017-2028)
7.2 North America Trastuzumab Emtansine for Injection Sales by Application (2017-2028)
7.3 North America Trastuzumab Emtansine for Injection Market Size by Country
7.3.1 North America Trastuzumab Emtansine for Injection Sales in Volume by Country (2017-2028)
7.3.2 North America Trastuzumab Emtansine for Injection Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Trastuzumab Emtansine for Injection Sales by Type (2017-2028)
8.2 Europe Trastuzumab Emtansine for Injection Sales by Application (2017-2028)
8.3 Europe Trastuzumab Emtansine for Injection Market Size by Country
8.3.1 Europe Trastuzumab Emtansine for Injection Sales in Volume by Country (2017-2028)
8.3.2 Europe Trastuzumab Emtansine for Injection Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Trastuzumab Emtansine for Injection Sales by Type (2017-2028)
9.2 Asia-Pacific Trastuzumab Emtansine for Injection Sales by Application (2017-2028)
9.3 Asia-Pacific Trastuzumab Emtansine for Injection Market Size by Region
9.3.1 Asia-Pacific Trastuzumab Emtansine for Injection Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Trastuzumab Emtansine for Injection Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Trastuzumab Emtansine for Injection Sales by Type (2017-2028)
10.2 South America Trastuzumab Emtansine for Injection Sales by Application (2017-2028)
10.3 South America Trastuzumab Emtansine for Injection Market Size by Country
10.3.1 South America Trastuzumab Emtansine for Injection Sales in Volume by Country (2017-2028)
10.3.2 South America Trastuzumab Emtansine for Injection Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Trastuzumab Emtansine for Injection Sales by Type (2017-2028)
11.2 Middle East & Africa Trastuzumab Emtansine for Injection Sales by Application (2017-2028)
11.3 Middle East & Africa Trastuzumab Emtansine for Injection Market Size by Country
11.3.1 Middle East & Africa Trastuzumab Emtansine for Injection Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Trastuzumab Emtansine for Injection Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Trastuzumab Emtansine for Injection and Key Manufacturers
12.2 Manufacturing Costs Percentage of Trastuzumab Emtansine for Injection
12.3 Trastuzumab Emtansine for Injection Production Process
12.4 Trastuzumab Emtansine for Injection Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Trastuzumab Emtansine for Injection Typical Distributors
13.3 Trastuzumab Emtansine for Injection Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer